Advances in immunotyping of colorectal cancer

Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Understanding the complexity and...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1259461
Main Authors Wu, Yinhang, Zhuang, Jing, Qu, Zhanbo, Yang, Xi, Han, Shuwen
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 09.10.2023
Subjects
colorectal cancer
colorectal cancer subtypes
immune subtype
Immunology
immunotherapy
tumor immune microenvironment
Online AccessGet full text

Cover

Abstract Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Understanding the complexity and heterogeneity of the tumor immune microenvironment (TIME) and identifying immune-related CRC subtypes will improve antitumor immunotherapy. Here, we review the current status of immunotherapy and typing schemes for CRC. Immune subtypes have been identified based on TIME and prognostic gene signatures that can both partially explain clinical responses to immune checkpoint inhibitors and the prognosis of patients with CRC. Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.
AbstractList Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Understanding the complexity and heterogeneity of the tumor immune microenvironment (TIME) and identifying immune-related CRC subtypes will improve antitumor immunotherapy. Here, we review the current status of immunotherapy and typing schemes for CRC. Immune subtypes have been identified based on TIME and prognostic gene signatures that can both partially explain clinical responses to immune checkpoint inhibitors and the prognosis of patients with CRC. Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.
Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Understanding the complexity and heterogeneity of the tumor immune microenvironment (TIME) and identifying immune-related CRC subtypes will improve antitumor immunotherapy. Here, we review the current status of immunotherapy and typing schemes for CRC. Immune subtypes have been identified based on TIME and prognostic gene signatures that can both partially explain clinical responses to immune checkpoint inhibitors and the prognosis of patients with CRC. Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Understanding the complexity and heterogeneity of the tumor immune microenvironment (TIME) and identifying immune-related CRC subtypes will improve antitumor immunotherapy. Here, we review the current status of immunotherapy and typing schemes for CRC. Immune subtypes have been identified based on TIME and prognostic gene signatures that can both partially explain clinical responses to immune checkpoint inhibitors and the prognosis of patients with CRC. Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.
Author Han, Shuwen
Qu, Zhanbo
Yang, Xi
Zhuang, Jing
Wu, Yinhang
AuthorAffiliation 2 Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou , Huzhou , China
1 Huzhou Central Hospital, Affiliated Central Hospital HuZhou University , Huzhou , China
3 Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University , Huzhou , China
AuthorAffiliation_xml – name: 2 Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou , Huzhou , China
– name: 1 Huzhou Central Hospital, Affiliated Central Hospital HuZhou University , Huzhou , China
– name: 3 Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University , Huzhou , China
Author_xml – sequence: 1
  givenname: Yinhang
  surname: Wu
  fullname: Wu, Yinhang
– sequence: 2
  givenname: Jing
  surname: Zhuang
  fullname: Zhuang, Jing
– sequence: 3
  givenname: Zhanbo
  surname: Qu
  fullname: Qu, Zhanbo
– sequence: 4
  givenname: Xi
  surname: Yang
  fullname: Yang, Xi
– sequence: 5
  givenname: Shuwen
  surname: Han
  fullname: Han, Shuwen
BookMark eNp9kUtLxDAUhYMo-PwDrrp00zGvpslKRHyB4EbXIUlvxkibjElH8N_bOiOoC7NJbu45371wDtFuTBEQOiV4wZhU5z4Mw3pBMWULQhvFBdlBB0QIXjNK-e6P9z46KeUVT4crxlhzgOrL7t1EB6UKsZo5MY0fqxCXVfKVS33K4EbTV24W5WO0501f4GR7H6Hnm-unq7v64fH2_uryoXaci7EWltGOtNI654WS3ME0DmM6FSAcplaCFCCxbQjF2DeKtQxU23aNsN5hzI7Q_YbbJfOqVzkMJn_oZIL--kh5qU0eg-tBt5RBYyw1ylBuHZ1GgzHEKuJ5542dWBcb1mptB-gcxDGb_hf0dyeGF71M75rgRmGp-EQ42xJyeltDGfUQioO-NxHSumgqJWkJE2yWyo3U5VRKBq9dGM0Y0owO_cTUc2T6KzI9R6a3kU1W-sf6veI_pk9HwZ15
CitedBy_id crossref_primary_10_1007_s00432_024_05992_z
crossref_primary_10_2147_CMAR_S500215
crossref_primary_10_3748_wjg_v30_i13_1815
crossref_primary_10_1016_j_prp_2023_155000
Cites_doi 10.1038/nm.3967
10.1089/omi.2012.0039
10.1016/j.omto.2019.08.008
10.1126/science.1129139
10.1371/journal.pmed.1001453
10.7150/ijbs.69808
10.1016/j.cell.2014.12.033
10.1186/s40425-018-0479-7
10.1038/s41590-020-0650-4
10.1371/journal.pone.0103159
10.1016/j.immuni.2019.12.011
10.1038/521S1a
10.1136/gutjnl-2016-313498
10.3390/vaccines9060614
10.1038/s41588-020-0636-z
10.1038/s41586-022-04772-4
10.1016/j.omto.2021.02.001
10.1186/s13046-021-02076-5
10.1016/j.lfs.2020.118368
10.1016/S0140-6736(18)30789-X
10.1038/s41573-018-0007-y
10.1158/2159-8290.CD-20-1680
10.1038/nature24673
10.3390/cancers12010164
10.1038/nature21349
10.1016/j.critrevonc.2022.103597
10.1002/jev2.12289
10.1016/j.stem.2011.10.008
10.1053/j.gastro.2009.11.005
10.1126/science.abb9847
10.1056/NEJMoa1609279
10.1093/gastro/goaa045
10.1056/NEJMoa1507643
10.3892/ol.2020.11605
10.1111/jcmm.16696
10.1038/s41586-019-1170-y
10.1056/NEJMoa1500596
10.1038/bjc.2017.178
10.1038/s41598-021-01627-2
10.1158/0008-5472.CAN-15-0255
10.7554/eLife.57243
10.1177/1534735419876351
10.1186/s13550-020-0600-z
10.1016/j.immuni.2016.02.025
10.1038/s41591-018-0136-1
10.23922/jarc.2020-064
10.1016/j.gene.2021.146177
10.1038/modpathol.2017.156
10.3389/fmolb.2020.604252
10.1016/j.ejca.2019.09.008
10.1080/21645515.2020.1854604
10.1186/s13045-020-00946-7
10.1016/j.semcancer.2018.02.010
10.1016/j.ejphar.2020.173819
10.1016/j.tranon.2021.101174
10.1158/0008-5472.CAN-14-1592
10.1038/mt.2010.272
10.3389/fimmu.2022.968089
10.7150/thno.52717
10.1158/1078-0432.CCR-09-1431
10.7150/thno.58390
10.1016/j.ejca.2016.06.008
10.1158/1078-0432.CCR-13-3271
10.1093/annonc/mdw235
10.1016/j.cell.2018.09.035
10.1158/0008-5472.CAN-08-2654
10.1155/2020/6901472
10.1038/nri.2017.89
10.1016/j.trecan.2016.07.008
10.1016/j.cell.2023.02.039
10.1097/00000441-189305000-00001
10.1038/s41551-021-00834-6
10.1038/nrc3245
10.1016/j.immuni.2018.03.023
10.3390/ijms22168470
10.1177/1758834015572343
10.1016/S0140-6736(16)00561-4
10.1038/s41598-021-98966-x
10.1016/j.cell.2017.08.027
10.1200/JCO.2017.76.9901
10.1016/j.intimp.2020.106868
10.1038/s41577-020-0275-8
10.1007/s00262-020-02525-8
10.1038/nm.3175
10.1093/jnci/djz093
10.1002/jcb.29675
10.1007/s11033-021-06752-9
10.1016/j.canlet.2019.01.015
10.1002/cam4.3694
10.1158/1078-0432.CCR-18-1984
10.1158/1078-0432.CCR-15-1507
10.1038/s41422-020-00441-1
10.1084/jem.20182395
10.1016/j.molmed.2021.06.014
10.1038/nature14011
10.1126/science.aad0095
10.1016/j.annonc.2022.10.003
10.7150/ijbs.64077
10.1016/j.jtho.2016.01.015
10.1007/s00262-018-2289-7
10.1111/cas.14216
10.1155/2022/5827544
10.1038/s41591-018-0014-x
10.1016/j.ygeno.2020.02.015
10.1136/jitc-2020-000673
10.1155/2016/6261721
ContentType Journal Article
Copyright Copyright © 2023 Wu, Zhuang, Qu, Yang and Han.
Copyright © 2023 Wu, Zhuang, Qu, Yang and Han 2023 Wu, Zhuang, Qu, Yang and Han
Copyright_xml – notice: Copyright © 2023 Wu, Zhuang, Qu, Yang and Han.
– notice: Copyright © 2023 Wu, Zhuang, Qu, Yang and Han 2023 Wu, Zhuang, Qu, Yang and Han
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fimmu.2023.1259461
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_723e5ab2a9a24bc2b32eaa1b91f4dfab
PMC10590894
10_3389_fimmu_2023_1259461
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c446t-6b32d178bccf6984ce493002f69e6c02b8e86e80b51200f59373e977d56bfc003
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:31:38 EDT 2025
Thu Aug 21 18:35:58 EDT 2025
Fri Jul 11 12:20:08 EDT 2025
Tue Jul 01 03:33:37 EDT 2025
Thu Apr 24 23:12:42 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c446t-6b32d178bccf6984ce493002f69e6c02b8e86e80b51200f59373e977d56bfc003
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Christian Augsberger, AstraZeneca, Germany; Jaya Lakshmi Thangaraj, University of California, San Diego, United States
These authors have contributed equally to this work and share first authorship
Edited by: Youssef Errami, Tulane University, United States
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2023.1259461
PQID 2881713634
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_723e5ab2a9a24bc2b32eaa1b91f4dfab
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10590894
proquest_miscellaneous_2881713634
crossref_citationtrail_10_3389_fimmu_2023_1259461
crossref_primary_10_3389_fimmu_2023_1259461
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-10-09
PublicationDateYYYYMMDD 2023-10-09
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-09
  day: 09
PublicationDecade 2020
PublicationTitle Frontiers in immunology
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Meng (B9) 2022; 11
Marisa (B61) 2013; 10
Chibaudel (B3) 2015; 7
Taube (B43) 2018; 31
Rooney (B53) 2015; 160
Chen (B73) 2020; 20
Yang (B32) 2019; 110
Zhu (B93) 2022; 818
de Sousa (B64) 2011; 9
Bäck (B11) 2020; 10
Bebber (B97) 2020; 12
Lee (B69) 2020; 52
Borghaei (B18) 2015; 373
Tang (B31) 2020; 8
Jorissen (B63) 2009; 15
Tang (B98) 2021; 31
Lopes (B12) 2020; 8
Binnewies (B27) 2018; 24
Germano (B47) 2017; 552
Rezasoltani (B106) 2021; 10
Sharma (B16) 2021; 11
Tan (B44) 2020; 121
Liu (B45) 2021; 11
Zheng (B33) 2021; 11
Chong (B34) 2021; 11
Mittra (B82) 2021; 17
Weiden (B81) 2018; 18
Sanmamed (B58) 2018; 175
Khan (B6) 2021; 9
Wang (B25) 2021; 22
Xu (B101) 2021; 27
Badrinath (B7) 2022; 606
Yoon (B29) 2019; 25
Ma (B24) 2019; 9
Parkhurst (B83) 2011; 19
Pagès (B39) 2018; 391
Fridman (B76) 2012; 12
Li (B75) 2020; 88
Chen (B49) 2017; 541
Herbst (B54) 2014; 515
Franke (B20) 2019; 111
Kirzin (B66) 2014; 9
Brody (B80) 2015; 521
Cervantes (B2) 2023; 34
Xu (B72) 2022; 30
Rosenberg (B19) 2016; 387
Ooki (B88) 2021; 5
Galon (B55) 2019; 18
Meng (B92) 2021; 20
Ribas (B14) 2017; 170
Krishna (B84) 2020; 370
Shen (B96) 2020; 112
Hegde (B50) 2016; 22
Liu (B74) 2021; 25
Caballero-Baños (B87) 2016; 64
Smith (B65) 2010; 138
Wang (B102) 2019; 569
Camus (B36) 2009; 69
Wang (B8) 2022; 6
Jiang (B37) 2018; 24
Van Cutsem (B4) 2016; 27
Maleki Vareki (B46) 2018; 6
Tran (B85) 2016; 375
Mao (B62) 2022; 13
Taube (B77) 2014; 20
Fritz (B17) 2019; 216
Bremnes (B51) 2016; 11
Kishore (B22) 2021; 893
Van Allen (B52) 2015; 350
Thorsson (B91) 2018; 48
Li (B104) 2019; 447
Hegde (B56) 2020; 52
Tang (B100) 2020; 13
Shulman (B103) 2020; 21
Demurtas (B79) 2017; 117
Sharma (B15) 2020; 20
Galon (B28) 2006; 313
Zhang (B99) 2020; 2020
Li (B40) 2020; 261
Barrett (B26) 2020; 9
Guinney (B30) 2015; 21
Sadanandam (B59) 2013; 19
Zhou (B70) 2019; 68
Laibe (B68) 2012; 16
Gao (B95) 2021; 11
Luo (B35) 2022; 18
Wen (B71) 2020; 7
Tripathi (B67) 2014; 74
Kather (B89) 2018; 52
Zhou (B94) 2020; 69
Fanale (B48) 2022; 170
Soldevilla (B90) 2019; 123
Krokhotin (B10) 2019; 15
Mlecnik (B38) 2016; 44
Teng (B57) 2015; 75
Fessler (B60) 2016; 2
Dagher (B86) 2023; 186
Parcesepe (B78) 2016; 6261721
Yi (B105) 2019; 18
Ghaffari (B13) 2021; 40
Coley (B41) 1893; 105
Le (B23) 2015; 372
Xi (B1) 2021; 14
Cremonesi (B107) 2018; 67
Overman (B42) 2018; 36
Kumar (B5) 2021; 48
Fan (B21) 2021; 17
References_xml – volume: 21
  year: 2015
  ident: B30
  article-title: The consensus molecular subtypes of colorectal cancer
  publication-title: Nat Med
  doi: 10.1038/nm.3967
– volume: 16
  year: 2012
  ident: B68
  article-title: A seven-gene signature aggregates a subgroup of stage II colon cancers with stage III
  publication-title: Omics
  doi: 10.1089/omi.2012.0039
– volume: 15
  year: 2019
  ident: B10
  article-title: Computationally guided design of single-chain variable fragment improves specificity of chimeric antigen receptors
  publication-title: Mol Ther Oncolytics
  doi: 10.1016/j.omto.2019.08.008
– volume: 313
  year: 2006
  ident: B28
  article-title: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
  publication-title: Science
  doi: 10.1126/science.1129139
– volume: 10
  start-page: 21
  year: 2013
  ident: B61
  article-title: Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value
  publication-title: PloS Med
  doi: 10.1371/journal.pmed.1001453
– volume: 18
  year: 2022
  ident: B35
  article-title: Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.69808
– volume: 160
  start-page: 48
  year: 2015
  ident: B53
  article-title: Molecular and genetic properties of tumors associated with local immune cytolytic activity
  publication-title: Cell
  doi: 10.1016/j.cell.2014.12.033
– volume: 6
  start-page: 018
  year: 2018
  ident: B46
  article-title: High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-018-0479-7
– volume: 21
  year: 2020
  ident: B103
  article-title: The RNA modification N(6)-methyladenosine as a novel regulator of the immune system
  publication-title: Nat Immunol
  doi: 10.1038/s41590-020-0650-4
– volume: 9
  year: 2014
  ident: B66
  article-title: Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study
  publication-title: PloS One
  doi: 10.1371/journal.pone.0103159
– volume: 52
  start-page: 17
  year: 2020
  ident: B56
  article-title: Top 10 challenges in cancer immunotherapy
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.12.011
– volume: 521
  start-page: S1
  year: 2015
  ident: B80
  article-title: Colorectal cancer
  publication-title: Nature
  doi: 10.1038/521S1a
– volume: 67
  year: 2018
  ident: B107
  article-title: Gut microbiota modulate T cell trafficking into human colorectal cancer
  publication-title: Gut
  doi: 10.1136/gutjnl-2016-313498
– volume: 9
  start-page: 614
  year: 2021
  ident: B6
  article-title: The evolution of cancer immunotherapy
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines9060614
– volume: 52
  start-page: 594
  year: 2020
  ident: B69
  article-title: Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer
  publication-title: Nat Genet
  doi: 10.1038/s41588-020-0636-z
– volume: 606
  year: 2022
  ident: B7
  article-title: A vaccine targeting resistant tumours by dual T cell plus NK cell attack
  publication-title: Nature
  doi: 10.1038/s41586-022-04772-4
– volume: 20
  year: 2021
  ident: B92
  article-title: Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy
  publication-title: Mol Ther Oncolytics
  doi: 10.1016/j.omto.2021.02.001
– volume: 40
  start-page: 269
  year: 2021
  ident: B13
  article-title: CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-021-02076-5
– volume: 261
  start-page: 1
  year: 2020
  ident: B40
  article-title: An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2020.118368
– volume: 391
  year: 2018
  ident: B39
  article-title: International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(18)30789-X
– volume: 18
  start-page: 197
  year: 2019
  ident: B55
  article-title: Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
  publication-title: Nat Rev Drug Discovery
  doi: 10.1038/s41573-018-0007-y
– volume: 11
  year: 2021
  ident: B16
  article-title: The next decade of immune checkpoint therapy
  publication-title: Cancer Discovery
  doi: 10.1158/2159-8290.CD-20-1680
– volume: 552
  year: 2017
  ident: B47
  article-title: Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
  publication-title: Nature
  doi: 10.1038/nature24673
– volume: 12
  start-page: 164
  year: 2020
  ident: B97
  article-title: Ferroptosis in cancer cell biology
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12010164
– volume: 541
  year: 2017
  ident: B49
  article-title: Elements of cancer immunity and the cancer-immune set point
  publication-title: Nature
  doi: 10.1038/nature21349
– volume: 170
  start-page: 13
  year: 2022
  ident: B48
  article-title: Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2022.103597
– volume: 11
  year: 2022
  ident: B9
  article-title: Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity
  publication-title: J Extracell Vesicles
  doi: 10.1002/jev2.12289
– volume: 9
  year: 2011
  ident: B64
  article-title: Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2011.10.008
– volume: 138
  year: 2010
  ident: B65
  article-title: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2009.11.005
– volume: 370
  year: 2020
  ident: B84
  article-title: Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
  publication-title: Science
  doi: 10.1126/science.abb9847
– volume: 375
  year: 2016
  ident: B85
  article-title: T-cell transfer therapy targeting mutant KRAS in cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1609279
– volume: 8
  year: 2020
  ident: B31
  article-title: The tumor immune microenvironment transcriptomic subtypes of colorectal cancer for prognosis and development of precise immunotherapy
  publication-title: Gastroenterol Rep
  doi: 10.1093/gastro/goaa045
– volume: 373
  year: 2015
  ident: B18
  article-title: Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1507643
– volume: 20
  year: 2020
  ident: B73
  article-title: Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy
  publication-title: Oncol Lett
  doi: 10.3892/ol.2020.11605
– volume: 25
  year: 2021
  ident: B74
  article-title: Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.16696
– volume: 569
  year: 2019
  ident: B102
  article-title: CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy
  publication-title: Nature
  doi: 10.1038/s41586-019-1170-y
– volume: 372
  year: 2015
  ident: B23
  article-title: PD-1 blockade in tumors with mismatch-repair deficiency
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1500596
– volume: 117
  year: 2017
  ident: B79
  article-title: The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2017.178
– volume: 11
  start-page: 021
  year: 2021
  ident: B95
  article-title: Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-01627-2
– volume: 75
  year: 2015
  ident: B57
  article-title: Classifying cancers based on T-cell infiltration and PD-L1
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-15-0255
– volume: 9
  year: 2020
  ident: B26
  article-title: Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy
  publication-title: Elife
  doi: 10.7554/eLife.57243
– volume: 18
  start-page: 1534735419876351
  year: 2019
  ident: B105
  article-title: Manipulating gut microbiota composition to enhance the therapeutic effect of cancer immunotherapy
  publication-title: Integr Cancer Ther
  doi: 10.1177/1534735419876351
– volume: 10
  start-page: 10
  year: 2020
  ident: B11
  article-title: Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
  publication-title: EJNMMI Res
  doi: 10.1186/s13550-020-0600-z
– volume: 44
  start-page: 698
  year: 2016
  ident: B38
  article-title: Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.02.025
– volume: 24
  year: 2018
  ident: B37
  article-title: Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0136-1
– volume: 5
  start-page: 11
  year: 2021
  ident: B88
  article-title: Immunotherapy in colorectal cancer: current and future strategies
  publication-title: J Anus Rectum Colon
  doi: 10.23922/jarc.2020-064
– volume: 818
  start-page: 20
  year: 2022
  ident: B93
  article-title: Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma
  publication-title: Gene
  doi: 10.1016/j.gene.2021.146177
– volume: 31
  year: 2018
  ident: B43
  article-title: Implications of the tumor immune microenvironment for staging and therapeutics
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2017.156
– volume: 7
  year: 2020
  ident: B71
  article-title: Prognostic model of colorectal cancer constructed by eight immune-related genes
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2020.604252
– volume: 123
  year: 2019
  ident: B90
  article-title: The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2019.09.008
– volume: 17
  year: 2021
  ident: B82
  article-title: The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors
  publication-title: Hum Vaccin Immunother
  doi: 10.1080/21645515.2020.1854604
– volume: 13
  start-page: 020
  year: 2020
  ident: B100
  article-title: Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-020-00946-7
– volume: 52
  year: 2018
  ident: B89
  article-title: Genomics and emerging biomarkers for immunotherapy of colorectal cancer
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2018.02.010
– volume: 893
  start-page: 29
  year: 2021
  ident: B22
  article-title: Current advancements and future perspectives of immunotherapy in colorectal cancer research
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2020.173819
– volume: 14
  start-page: 101174
  year: 2021
  ident: B1
  article-title: Global colorectal cancer burden in 2020 and projections to 2040
  publication-title: Trans Oncol
  doi: 10.1016/j.tranon.2021.101174
– volume: 74
  year: 2014
  ident: B67
  article-title: Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-1592
– volume: 19
  year: 2011
  ident: B83
  article-title: T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
  publication-title: Mol Ther
  doi: 10.1038/mt.2010.272
– volume: 13
  year: 2022
  ident: B62
  article-title: The immune phenotypes and different immune escape mechanisms in colorectal cancer
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.968089
– volume: 11
  year: 2021
  ident: B34
  article-title: m(6)A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer
  publication-title: Theranostics
  doi: 10.7150/thno.52717
– volume: 15
  year: 2009
  ident: B63
  article-title: Metastasis-Associated gene expression changes predict poor outcomes in patients with dukes stage B and C colorectal cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-1431
– volume: 11
  year: 2021
  ident: B45
  article-title: Turning cold tumors into hot tumors by improving T-cell infiltration
  publication-title: Theranostics
  doi: 10.7150/thno.58390
– volume: 64
  year: 2016
  ident: B87
  article-title: Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2016.06.008
– volume: 20
  year: 2014
  ident: B77
  article-title: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-3271
– volume: 27
  year: 2016
  ident: B4
  article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw235
– volume: 175
  year: 2018
  ident: B58
  article-title: A paradigm shift in cancer immunotherapy: from enhancement to normalization
  publication-title: Cell
  doi: 10.1016/j.cell.2018.09.035
– volume: 69
  year: 2009
  ident: B36
  article-title: Coordination of intratumoral immune reaction and human colorectal cancer recurrence
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-2654
– volume: 2020
  start-page: 1675613
  year: 2020
  ident: B99
  article-title: IMCA induces ferroptosis mediated by SLC7A11 through the AMPK/mTOR pathway in colorectal cancer
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2020/6901472
– volume: 18
  year: 2018
  ident: B81
  article-title: Synthetic immune niches for cancer immunotherapy
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri.2017.89
– volume: 2
  year: 2016
  ident: B60
  article-title: Colorectal cancer subtypes: developmental origin and microenvironmental regulation
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2016.07.008
– volume: 186
  start-page: 1814
  year: 2023
  ident: B86
  article-title: Advances in cancer immunotherapies
  publication-title: Cell
  doi: 10.1016/j.cell.2023.02.039
– volume: 105
  start-page: 487
  year: 1893
  ident: B41
  article-title: The treatment of Malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases
  publication-title: Am J Med Sci
  doi: 10.1097/00000441-189305000-00001
– volume: 6
  start-page: 44
  year: 2022
  ident: B8
  article-title: Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria
  publication-title: Nat BioMed Eng
  doi: 10.1038/s41551-021-00834-6
– volume: 12
  start-page: 298
  year: 2012
  ident: B76
  article-title: The immune contexture in human tumours: impact on clinical outcome
  publication-title: Nat Rev Cancer.
  doi: 10.1038/nrc3245
– volume: 48
  start-page: 812
  year: 2018
  ident: B91
  article-title: The immune landscape of cancer
  publication-title: Immunity
  doi: 10.1016/j.immuni.2018.03.023
– volume: 22
  start-page: 8470
  year: 2021
  ident: B25
  article-title: Tumor-associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22168470
– volume: 7
  year: 2015
  ident: B3
  article-title: Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review
  publication-title: Ther Adv Med Oncol
  doi: 10.1177/1758834015572343
– volume: 387
  year: 2016
  ident: B19
  article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)00561-4
– volume: 11
  start-page: 021
  year: 2021
  ident: B33
  article-title: Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-98966-x
– volume: 170
  start-page: 1109
  year: 2017
  ident: B14
  article-title: Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2017.08.027
– volume: 36
  year: 2018
  ident: B42
  article-title: Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-Deficient/Microsatellite instability-High metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2017.76.9901
– volume: 88
  start-page: 6
  year: 2020
  ident: B75
  article-title: Identification and validation of an immune prognostic signature in colorectal cancer
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2020.106868
– volume: 20
  year: 2020
  ident: B15
  article-title: Dissecting the mechanisms of immune checkpoint therapy
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-0275-8
– volume: 69
  year: 2020
  ident: B94
  article-title: Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-020-02525-8
– volume: 19
  year: 2013
  ident: B59
  article-title: A colorectal cancer classification system that associates cellular phenotype and responses to therapy
  publication-title: Nat Med
  doi: 10.1038/nm.3175
– volume: 111
  year: 2019
  ident: B20
  article-title: Immunotherapy for colorectal cancer: A review of current and novel therapeutic approaches
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djz093
– volume: 121
  year: 2020
  ident: B44
  article-title: Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.29675
– volume: 48
  year: 2021
  ident: B5
  article-title: Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets
  publication-title: Mol Biol Rep
  doi: 10.1007/s11033-021-06752-9
– volume: 447
  year: 2019
  ident: B104
  article-title: Gut microbiome and cancer immunotherapy
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2019.01.015
– volume: 10
  year: 2021
  ident: B106
  article-title: Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
  publication-title: Cancer Med
  doi: 10.1002/cam4.3694
– volume: 25
  year: 2019
  ident: B29
  article-title: Intertumoral heterogeneity of CD3(+) and CD8(+) T-Cell densities in the microenvironment of DNA mismatch-Repair-Deficient colon cancers: implications for prognosis
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1984
– volume: 22
  year: 2016
  ident: B50
  article-title: The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1507
– volume: 31
  year: 2021
  ident: B98
  article-title: Ferroptosis: molecular mechanisms and health implications
  publication-title: Cell Res
  doi: 10.1038/s41422-020-00441-1
– volume: 216
  year: 2019
  ident: B17
  article-title: Development of immune checkpoint therapy for cancer
  publication-title: J Exp Med
  doi: 10.1084/jem.20182395
– volume: 27
  year: 2021
  ident: B101
  article-title: Ferroptosis in the tumor microenvironment: perspectives for immunotherapy
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2021.06.014
– volume: 9
  year: 2019
  ident: B24
  article-title: How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy
  publication-title: Am J Cancer Res
– volume: 515
  year: 2014
  ident: B54
  article-title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
  publication-title: Nature
  doi: 10.1038/nature14011
– volume: 350
  year: 2015
  ident: B52
  article-title: Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
  publication-title: Science
  doi: 10.1126/science.aad0095
– volume: 34
  start-page: 10
  year: 2023
  ident: B2
  article-title: Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2022.10.003
– volume: 17
  year: 2021
  ident: B21
  article-title: Immunotherapy in colorectal cancer: current achievements and future perspective
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.64077
– volume: 11
  start-page: 789
  year: 2016
  ident: B51
  article-title: The role of tumor-Infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2016.01.015
– volume: 68
  year: 2019
  ident: B70
  article-title: Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I–III colon cancer
  publication-title: Cancer immunology immunotherapy
  doi: 10.1007/s00262-018-2289-7
– volume: 110
  year: 2019
  ident: B32
  article-title: Immune cell infiltration as a biomarker for the diagnosis and prognosis of digestive system cancer
  publication-title: Cancer Sci
  doi: 10.1111/cas.14216
– volume: 30
  year: 2022
  ident: B72
  article-title: Identification of immune-related lncRNA pairs and construction and validation of a new prognostic signature of colon cancer
  publication-title: Can J Gastroenterol Hepatol
  doi: 10.1155/2022/5827544
– volume: 24
  year: 2018
  ident: B27
  article-title: Understanding the tumor immune microenvironment (TIME) for effective therapy
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0014-x
– volume: 112
  year: 2020
  ident: B96
  article-title: Identification and validation of immune-related lncRNA prognostic signature for breast cancer
  publication-title: Genomics
  doi: 10.1016/j.ygeno.2020.02.015
– volume: 8
  year: 2020
  ident: B12
  article-title: ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-000673
– volume: 6261721
  start-page: 23
  year: 2016
  ident: B78
  article-title: Cancer-associated immune resistance and evasion of immune surveillance in colorectal cancer
  publication-title: Gastroenterol Res Pract
  doi: 10.1155/2016/6261721
SSID ssj0000493335
Score 2.3976605
SecondaryResourceType review_article
Snippet Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1259461
SubjectTerms colorectal cancer
colorectal cancer subtypes
immune subtype
Immunology
immunotherapy
tumor immune microenvironment
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NS8MwFA8yELyIn1i_qOBNurVJmqXHKY4h6MnBbiFJE5y4TrbusP_e99purBe9eGybkOS9vrzfy8fvEXLvKIQ4gOSjXFobcQamqCWYu46t5pynANJxQf_1TYzG_GWSTnZSfeGZsJoeuBZcr0-ZS7WhOtOUG0sNo07rxGSJ57nXBmdf8Hk7wdRnjXsZY2l9SwaisKznp7PZqovJwrvg0zMukpYnqgj7WyizfUZyx-kMj8hhgxbDQd3LY7LnihOyX-ePXJ-SaFDv4C_DaRFiy8W8XOMFqHDuQ6SjxukM6lsstDgj4-Hz-9MoavIfRBaCtDISMNY86UtjrReZ5NbBqGAGgwcnbEyNdFI4GRtw2nHsU0AazAGey1NhvAVzPSedYl64CxKyinqPGe9cwr2RmfDomB0ALhEzLwOSbGShbEMOjjkqvhQECSg_VclPofxUI7-APGzrfNfUGL-WfkQRb0sirXX1ApStGmWrv5QdkLuNghSYAe5t6MLNV0tFpUwg3haMB0S2NNdqsf2lmH5UhNpJlfk945f_0ccrcoDjrg78ZdekUy5W7gaAS2luq3_0B1K_7Ig
  priority: 102
  providerName: Directory of Open Access Journals
Title Advances in immunotyping of colorectal cancer
URI https://www.proquest.com/docview/2881713634
https://pubmed.ncbi.nlm.nih.gov/PMC10590894
https://doaj.org/article/723e5ab2a9a24bc2b32eaa1b91f4dfab
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA7LiuBFfOL6ooI36do2aTY9iKi4LoKeXNhbSLKJrmir-wD33zuTdsWCevBSaJsh5Esm800eM4Qc2wRcHGDy4VAYEzIKqqgEqLuKjGKMpUDScUH_7p73-ux2kA4aZJHuqAJw8qNrh_mk-uOX9sf7_BwU_gw9TrC3p270-jprYx7wNpjrjKE3tASWqYOKelfR_eeSDVNK0_LuzC-iNfvkw_jXuGf95OQ3U9RdI6sVhwwuyk5fJw2bb5DlMqvkfJOEF-W-_iQY5QHWnBfTOV6LCgoXYJBqnORA3mCh8Rbpd68frnphlRUhNOC6TUOuaTKMO0Ib43gmmLHQKpjX4MVyEyVaWMGtiDSY8ihyKfAPaoHlDVOunQEl3ibNvMjtDgmoD8hHtbM2Zk6LjDs01xZoGI-oEy0SL7CQpgoZjpkrXiS4Doif9PhJxE9W-LXIyZfMWxkw48_SlwjxV0kMdu0_FONHWemO7CTUpkonKlMJ0yYBAKxSsc5ix4ZO6RY5WnSQBOXAHQ-V22I2kYkQMAoop6xFRK3najXW_-SjJx9mO_b54DO2-3_RPbKCrfWH_7J90pyOZ_YASMxUH3rnH543g_jQj9JP2_b0HA
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advances+in+immunotyping+of+colorectal+cancer&rft.jtitle=Frontiers+in+immunology&rft.au=Wu%2C+Yinhang&rft.au=Zhuang%2C+Jing&rft.au=Qu%2C+Zhanbo&rft.au=Yang%2C+Xi&rft.date=2023-10-09&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=14&rft_id=info:doi/10.3389%2Ffimmu.2023.1259461&rft.externalDocID=PMC10590894
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon